Novartis Aktie

101,68 EUR +3,06 EUR +3,10 %

16:08:07

L&S

94,67 CHF +1,94 CHF +2,09 %

15:55:02

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.188,36 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

24.06.24ZacksHere's Why Novartis (NVS) is a Strong Value Stock

24.06.24ZacksAlcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS

20.06.24ZacksHere's Why Novartis (NVS) is a Strong Momentum Stock

10.06.24ZacksWhy Alcon (ALC) is a Top Momentum Stock for the Long-Term

06.06.24BenzingaItaly Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations

06.06.24ZacksWhy Novartis (NVS) is a Top Value Stock for the Long-Term

04.06.24ZacksWhy Novartis (NVS) is a Top Momentum Stock for the Long-Term

31.05.24BenzingaNovartis Sues to Block Maryland's New Drug Discount Law

31.05.24ZacksNovartis (NVS) Reports Positive Long-Term Data on CSU Drug

31.05.24GlobeNewswireNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

31.05.24GlobeNewswireNovartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

27.05.24ZacksNovartis (NVS) Presents Positive Data on Renal Drugs at ERA

25.05.24PR NewswireNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

25.05.24GlobeNewswireNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

25.05.24Dow JonesPress Release: Novartis atrasentan Phase III data -2-

25.05.24Dow JonesPress Release: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

25.05.24GlobeNewswireNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

25.05.24PR NewswireNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

25.05.24Budapest Business Journal Semmelweis Uni, Novartis Launch Cutting-Edge Lipid Management Center

24.05.24ZacksReasons to Include Alcon (ALC) in Your Portfolio Right Now

16.05.24GlobeNewswireNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

16.05.24Dow JonesPress Release: Novartis meets all tender offer -2-

16.05.24Dow JonesPress Release: Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

15.05.24GlobeNewswireNovartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

15.05.24Dow JonesPress Release: Novartis highlights pioneering -2-

15.05.24Dow JonesPress Release: Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

24.04.24GlobeNewswireNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

24.04.24Dow JonesPress Release: Novartis and Medicines for Malaria -2-

23.04.24GlobeNewswireNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

23.04.24Dow JonesPress Release: Novartis radioligand therapy -2-

23.04.24Dow JonesPress Release: Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuro...

23.04.24GlobeNewswireNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised

23.04.24Dow JonesPress Release: Novartis delivers double-digit -3-

23.04.24Dow JonesPress Release: Novartis delivers double-digit -2-

23.04.24Dow JonesPress Release: Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised

17.04.24GlobeNewswireNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

17.04.24Dow JonesPress Release: Novartis Kesimpta(R) six-year -2-

17.04.24Dow JonesPress Release: Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sc...

15.04.24GlobeNewswireNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

15.04.24PR NewswireNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.